CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018

 
• By Michael Cipriano

Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.

Pipeline
This is the actual pipeline sponsors use to get their applcaitions to FDA.

More from Product Reviews

More from Pink Sheet